Despite the inability to demonstrate angiogenic gene responses following EGFR activation in our study, EGFR remains an important feature as preclinical and clinical studies have demonstrated efficacy of EGFR inhibitors in advanced CRC, particularly in combination with chemo- and radiotherapy [87,88]. Here, EGFR is linked to colorectal carcinoma.